The FDA rejects Dextenza (again).

Give me the short version of Dextenza.

Dextenza is a dexamethasone insert, placed through the punctum into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days. Following treatment, Dextenza resorbs and exits the nasolacrimal system without need for removal. The trial investigated Dextenza for the treatment of post-surgical ocular inflammation and pain.

The first submission to the FDA was rejected because of concerns relating to the manufacturing process. This time it was rejected for the same reason.